ARTICLE | Clinical News
Deslorelle nasal mist: Phase II data; Phase II/III
July 3, 2000 7:00 AM UTC
Data from a 3-month study in 66 patients showed that daily administration of deslorelin reduced heavy bleeding associated with uterine fibroids. The product is in a 26-month Phase II/III study in 240 ...